Drugs / TYP03B
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05613205 | Nov 2022 → Dec 2023 | typhoid fever | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYP03B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05613205 ↗ |
| Modality | Vaccine | “2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.” NCT05613205 ↗ |
| Route | Intramuscular | “administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.” NCT05613205 ↗ |